The Next Drugs: The Future for Biosimilars
An Atlantic Policy Briefing

March 15, 2017
Washington, DC

New guidelines on naming and interchangeability from the Food and Drug Administration point to a changing role for biosimilars, while some of the Trump Administration's policy priorities, if implemented, could alter the dimensions of the American market.

The Atlantic gathered key stakeholders to examine the future for biosimilars domestically and abroad. What impact will the President's policies have on the industry? Will changes in regulation affect how many biosimilars are approved, and what impact will these have on ensuring that these drugs are safe and accessible for the patients who need them?


Watch full session videos

To view photos from this event, please visit our Facebook page

Presented by

Atlantic Live

Speakers

Agenda

  • Wednesday, March 15
  • 8:15 a.m.WelcomeMargaret Low, President, AtlanticLIVE
    Chester “Chip” Davis, Jr., President and Chief Executive Officer, Association for
    Accessible Medicines
  • 8:20 a.m.An Update from Capitol HillRepresentative Michael Burgess, MD (R-TX)
    With Joie Chen, Journalist and Contributor, AtlanticLIVE
  • 8:45 a.m.What the New Rules MeanJim Van Lieshout, Vice President, Market Access and Pharmacy Strategy, Apobiologix
    Len Lichtenfeld, MD, Deputy Chief Medical Officer, American Cancer Society
    David Fox, Partner, Hogan Lovells
    With Joie Chen, AtlanticLIVE
  • 9:15 a.m.ClosingMargaret Low, AtlanticLIVE

Underwriter

Also in This Series

Upcoming Events

  • Technology

    Franklin Foer In Conversation
    with Hanna Rosin

    Franklin Foer will join Hanna Rosin for a conversation about his new book World Without Mind and how consolidation of knowledge and information has changed how we contemplate the world.

  • Health Care

    Children and Cancer:
    An Atlantic Forum

    The Atlantic will break down the latest in immunotherapy and how it is being used to help young patients survive and thrive. And moving beyond anecdotal evidence, we'll examine how can big data can be used to track how pediatric cancers impact aspects of health for survivors down the road.

  • Health Care

    Cancer and the Community

    The Atlantic will explore challenges such as Nevada's shortage of doctors and specialists and learn what can be done from researchers, experts, stakeholders, survivors and patients living with cancer.